GlassScriptPhysician profile
Timothy Juwono
NPI 1639674872
$9,825.30
in general payments reported to CMS, 2019-2025
24 companies · $1,385 in 2025
The $1,385 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $528 · 2023: $4,653 · 2024: $3,259 · 2025: $1,385.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,489 · Travel and Lodging: $3,346 · Education: $462.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,489.47 |
| Travel and Lodging | $3,346.12 |
| Education | $461.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $5,610.66 | 2019-2025 | General - Erectile Dysfunction, Ams 700 Cxr Rte Kit, Lithovue |
| Coloplast Corp | $1,934.12 | 2023-2025 | Titan, Porges Coloplast |
| Astellas Pharma US INC | $642.10 | 2023-2025 | Xtandi |
| Abbvie INC. | $321.67 | 2024-2025 | |
| Janssen Biotech, INC. | $206.29 | 2024-2025 | Erleada, Akeega |
| Medtronic USA, INC. | $176.01 | 2019 | |
| Antares Pharma, INC. | $159.66 | 2023-2024 | Xyosted |
| Pfizer INC. | $126.96 | 2023-2024 | |
| Organogenesis INC. | $115.11 | 2023 | Puraply |
| Sumitomo Pharma America, INC. | $107.78 | 2023-2025 | Orgovyx, Gemtesa |
| Halozyme INC | $103.79 | 2023 | |
| Accord Healthcare, INC. | $60.99 | 2025 | |
| Laborie Medical Technologies Corp. | $34.29 | 2023-2024 | Urgent PC Neuromodulation System |
| Endo USA, INC. | $34.17 | 2025 | Xiaflex |
| Olympus America INC. | $23.49 | 2024 | Itind System |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Blue Earth Diagnostics | $22.31 | 2024 | |
| Merck Sharp & Dohme LLC | $21.48 | 2023 | Lynparza, Keytruda |
| 180 Medical, INC. | $21.36 | 2024 | |
| Endo Pharmaceuticals INC. | $19.54 | 2023 | Xiaflex |
| Novartis Pharmaceuticals Corporation | $19.38 | 2024 | |
| Karl Storz Endoscopy-America | $17.86 | 2024 | N.A. |
| Vertex Pharmaceuticals Incorporated | $16.98 | 2024 | |
| Davol INC. | $15.73 | 2025 | Arista |
| Sobi, INC | $13.57 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Juwono listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.